Shih, K., Arkenau, H.-T. & Infante, J. R. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74, 1993–2013 (2014).
Article CAS PubMed PubMed Central Google Scholar
Lalani, A.-K. A. et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur. Urol. 75, 100–110 (2019).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Article CAS PubMed PubMed Central Google Scholar
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Article CAS PubMed PubMed Central Google Scholar
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
Article CAS PubMed PubMed Central Google Scholar
Ascierto, P. A. et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 21, 1465–1477 (2020).
Article CAS PubMed Google Scholar
Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7, 387–401 (2019).
Article CAS PubMed Google Scholar
Choudhary, A., Davodeau, F., Moreau, A., Peyrat, M. A. & Jotereau, F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 154, 3932–3940 (1995).
Article CAS PubMed Google Scholar
Mami-Chouaib, F. et al. T cell target 1 (TCT.1): a novel target molecule for human non-major histocompatibility complex-restricted T lymphocytes. J. Exp. Med. 172, 1071–1082 (1990).
Article CAS PubMed Google Scholar
Kobayashi, H., Tanaka, Y., Yagi, J., Toma, H. & Uchiyama, T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50, 115–124 (2001).
Article CAS PubMed Google Scholar
Viey, E. et al. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338–1347 (2005).
Article CAS PubMed Google Scholar
Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447–1460 (2011).
Article CAS PubMed PubMed Central Google Scholar
Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872–879 (2012).
Article CAS PubMed Google Scholar
Hayday, A. C. γδ cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18, 975–1026 (2000).
Article CAS PubMed Google Scholar
Kabelitz, D., Serrano, R., Kouakanou, L., Peters, C. & Kalyan, S. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell. Mol. Immunol. 17, 925–939 (2020).
Article CAS PubMed PubMed Central Google Scholar
Cano, C. E. et al. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. Cell Rep. 36, 109359 (2021).
Article CAS PubMed Google Scholar
Payne, K. K. et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science 369, 942–949 (2020).
Article CAS PubMed PubMed Central Google Scholar
Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat. Rev. Immunol. 13, 88–100 (2013).
Article CAS PubMed PubMed Central Google Scholar
Paul, S. & Lal, G. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer: gamma-delta T cells in cancer. Int. J. Cancer 139, 976–985 (2016).
Article CAS PubMed Google Scholar
Silva-Santos, B., Serre, K. & Norell, H. γδ T cells in cancer. Nat. Rev. Immunol. 15, 683–691 (2015).
Article CAS PubMed Google Scholar
Wu, P. et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785–800 (2014).
Article CAS PubMed PubMed Central Google Scholar
Fleming, C. et al. Microbiota-activated CD103+ DCs stemming from microbiota adaptation specifically drive γδT17 proliferation and activation. Microbiome 5, 46 (2017).
Article PubMed PubMed Central Google Scholar
Peng, G. et al. Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27, 334–348 (2007).
Article CAS PubMed Google Scholar
Peters, C., Oberg, H.-H., Kabelitz, D. & Wesch, D. Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells. Cell. Mol. Life Sci. 71, 1943–1960 (2014).
Article CAS PubMed Google Scholar
Brandes, M., Willimann, K. & Moser, B. Professional antigen-presentation function by human γδ T cells. Science 309, 264–268 (2005).
Article CAS PubMed Google Scholar
Moser, B. & Brandes, M. γδ T cells: an alternative type of professional APC. Trends Immunol. 27, 112–118 (2006).
Article CAS PubMed Google Scholar
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
Article CAS PubMed PubMed Central Google Scholar
Ma, C. et al. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029–5036 (2012).
Article CAS PubMed Google Scholar
Dondero, A. et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. OncoImmunology 5, e1064578 (2016).
Daley, D. et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation. Cell 166, 1485–1499.e15 (2016).
Article CAS PubMed PubMed Central Google Scholar
Hu, G. et al. Tumor-infiltrating CD39+. γδ Tregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology 6, e1277305 (2017).
Article PubMed PubMed Central Google Scholar
Castella, B. et al. Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology 4, e1047580 (2015).
Article PubMed PubMed Central Google Scholar
Li, X. et al. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression. Exp. Cell. Res. 386, 111719 (2020).
Article CAS PubMed Google Scholar
Ness-Schwickerath, K. J., Jin, C. & Morita, C. T. Cytokine requirements for the differentiation and expansion of IL-17A– and IL-22–producing human Vγ2Vδ2 T cells. J. Immunol. 184, 7268–7280 (2010).
Article CAS PubMed Google Scholar
Dieli, F. et al. Characterization of lung γδ T cells following intranasal infection with Mycobacterium bovis bacillus Calmette–Guérin. J. Immunol. 170, 463–469 (2003).
Article CAS PubMed Google Scholar
Ryan, P. L. et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc. Natl Acad. Sci. USA 113, 14378–14383 (2016).
留言 (0)